Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Towards Biomarkers and Pathophysiology of Pulmonary Hypertension in Myeloproliferative Neoplasms

Franco Castillo Tokumori, Daniel C Choi, Pouneh Kermani, Katie Erdos, Alexander Gazda, Nathaniel Robichaud, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 6561.

https://doi.org/10.1182/blood-2024-209500

Published: 2024

Journal Articles

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2024-200997

Published: 2024

Journal Articles

Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

Alexander Gazda, Di Pan, Katie Erdos, Ghaith Abu-Zeinah, Alexandra Racanelli, Evelyn Horn, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3172.

https://doi.org/10.1182/blood-2024-210231

Published: 2024

Journal Articles

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Jr., Richard T. Silver, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2024-210703

Published: 2024

Journal Articles

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Daniel C Choi, Nassima Messali, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Franco Castillo Tokumori, Katie Erdos, Joseph M. Scandura, Narasimha Rao Uda, Heidi Lischer, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao

Blood (2024) 144 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2024-212169

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Neville Lee, Jr., Katie Erdos, Aqib Abdul Rahman, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah

Blood (2024) 144 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2024-211143

Published: 2024

Journal Articles

Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera

Katie Erdos, Neville Lee, Jr., Yushu Shi, Ghaith Abu-Zeinah, Joseph M. Scandura

Blood (2024) 144 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2024-210632

Published: 2024

Journal Articles

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Katie Erdos, Madhu M Ouseph, Julia Geyer, Neville Lee, Jr., Ghaith Abu-Zeinah, Joseph M. Scandura, Richard T. Silver

Blood (2023) 142 (Supplement 1): 3198.

https://doi.org/10.1182/blood-2023-187769

Published: 2023

Journal Articles

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

Spencer Krichevsky, Ghaith Abu-Zeinah, Katie Erdos, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2023-190684

Published: 2023

Journal Articles

JAK2 V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms

Daniel C Choi, Ghaith Abu-Zeinah, Pouneh Kermani, Nassima Messali, Maria Mia Yabut, Katie Erdos, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 1778.

https://doi.org/10.1182/blood-2023-190758

Published: 2023

Journal Articles

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Neville Lee, Jr., Katie Erdos, Joseph M. Scandura, Ghaith Abu-Zeinah, Richard T. Silver

Blood (2023) 142 (Supplement 1): 6434.

https://doi.org/10.1182/blood-2023-189643

Published: 2023

Journal Articles

Low Thrombosis Risk CALR Mutations Confer Higher Risk of Essential Thrombocythemia Progression

Katie Erdos, Neville Lee, Jr., Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Ghaith Abu-Zeinah, Richard T. Silver, Joseph M. Scandura

Blood (2023) 142 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2023-188952

Published: 2023

Journal Articles

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 3961–3962.

https://doi.org/10.1182/blood-2022-170893

Published: 2022

Journal Articles

JAK2 V617F Impairs T Cell Differentiation in Polycythemia Vera

Daniel C Choi, Ghaith Abu-Zeinah, Silvana Di Giandomenico, Katie Erdos, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6746–6747.

https://doi.org/10.1182/blood-2022-167785

Published: 2022

Journal Articles

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Ghaith Abu-Zeinah, Franco Castillo Tokumori, Katie Erdos, Imane Bouhali, Daniel C Choi, Richard T. Silver, Joseph Scandura

Blood (2022) 140 (Supplement 1): 6819–6820.

https://doi.org/10.1182/blood-2022-168283

Published: 2022

NARROW

Towards Biomarkers and Pathophysiology of Pulmonary Hypertension in Myeloproliferative Neoplasms

Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha

Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms

Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera

Marrow Hypercellularity Does Not Exclude the Diagnosis of Essential Thrombocythemia (ET)

Using Machine Learning to Predict Near-Term Thrombosis Risk in Patients with Polycythemia Vera

JAK2 V617F Impairs Lymphoid Differentiation in Myeloproliferative Neoplasms

Importance of Diagnosing Polycythemia Vera (PV) Patients (pts) Whose Hematocrit (HCT)/Hemoglobin (HGB) Are Less Than the Who 2022 Stipulated Criteria

Low Thrombosis Risk CALR Mutations Confer Higher Risk of Essential Thrombocythemia Progression

Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV

JAK2 V617F Impairs T Cell Differentiation in Polycythemia Vera

Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2 V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only